AIDS market seen reaching $43.28 billion by 2030

The global AIDS market is projected to grow from $35.53 billion in 2026 to $43.28 billion by 2030, driven by rising HIV infections, broader treatment access and expanding prevention programs. North America leads the market now, while Asia-Pacific is expected to grow fastest.

Why it matters: - The AIDS market reflects demand for diagnosis, treatment and prevention tools tied to global HIV trends. - Rising HIV infections are keeping pressure on healthcare systems, pharmacies and public health programs. - Growth in antiretroviral therapy, PrEP and PEP could widen access to care and improve outcomes.

What happened: - The Business Research Company projected the global acquired immunodeficiency syndrome market will rise from $35.53 billion in 2026 to $43.28 billion by 2030. - The report put the market at $33.75 billion in 2025 and $35.53 billion in 2026, implying 5.3% growth. - The forecast period from 2026 to 2030 carries a projected CAGR of 5.1%. - The report was released Oct. 28, 2026, from London. - A free sample report is available here. - The full report is available here.

The details: - Historical growth was driven by widespread HIV prevalence, awareness campaigns, government-backed treatment programs, first-generation antiretroviral drugs and more opportunistic infections linked to AIDS. - Forecast growth is expected to come from next-generation antiretroviral therapies, expanded PrEP and PEP programs, HIV vaccine research, digital health monitoring and public-private partnerships. - Emerging trends include broader use of antiretroviral therapy, stronger HIV diagnostics and surveillance, increased vaccine development and more integration between hospital and retail pharmacy services. - AIDS is a chronic and potentially fatal condition caused by HIV, which weakens the immune system by destroying CD4 T cells. - Managing AIDS typically requires ART, immune monitoring, opportunistic infection prevention and broader healthcare support. - Rising HIV cases are linked to unprotected sex, needle sharing, contaminated blood products, multiple sexual partners and weakened immune systems or other sexually transmitted infections. - ECDC data published in November 2024 showed 112,883 new HIV diagnoses across 47 of 53 countries in Europe in 2023. - The EU/EEA accounted for 24,731 of those diagnoses. - The crude HIV diagnosis rate rose to 12.7 per 100,000 population in 2023 from 12.4 in 2022, a 2.4% increase. - North America held the largest share of the AIDS market in 2025 because of established healthcare infrastructure and major investment in HIV/AIDS treatment and prevention. - Asia-Pacific is forecast to be the fastest-growing region, supported by better healthcare access, rising awareness and expanding treatment programs. - Other regions covered in the analysis include South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report points to a market shaped less by one product cycle and more by long-term public health needs. - Prevention tools and digital monitoring are becoming as important as treatment, suggesting a broader care ecosystem around HIV management. - Regional growth differences suggest mature markets will keep leading on spending while emerging markets drive faster expansion.

What's next: - The report expects next-generation therapies and prevention programs to remain the main growth engines through 2030. - Wider use of PrEP and PEP could expand the addressable market beyond treatment alone. - Vaccine research and stronger surveillance could influence future demand and public health policy. - The company said the report includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - The AIDS market is still growing, and the biggest gains appear tied to prevention, testing, treatment access and integrated care systems rather than any single breakthrough.